Galangin, as a Potential Anticancer Agent

Simple item page
dc.contributor.authorSingh, Dhirendra
dc.contributor.authorSaini, Arpit
dc.contributor.authorSingh, Randhir
dc.contributor.authorAgrawal, Rohini
dc.date.accessioned2024-01-21T10:55:02Z
dc.date.accessioned2024-08-14T07:44:19Z
dc.date.available2024-01-21T10:55:02Z
dc.date.available2024-08-14T07:44:19Z
dc.date.issued2022-04-07T00:00:00
dc.description.abstractCancer is a major global health issue and one of the main causes of mortality worldwide. In recent years, cancer mortality and morbidity rates have risen dramatically due to variety of factors. Despite therapeutic alternatives, chemotherapy medications have major adverse effects and many kinds of drug resistance that severely diminish their effectiveness. Galangin, 3,5,7-trihydroxyflavone, is considered as the bioactive constituent of galangal and honey. In general, galangin exhibits several pharmacological effects, such as anti-inflammatory, antioxidant, anticancer, and antiviral activities. The anticancer effects of galangin are mostly due to its abilities to inhibit cell cycle progression, inhibiting mitogen-activated protein kinase (MAPK), protein kinase B (Akt), or mammalian target of rapamycin (mTOR) activity leading to apoptotic cell death by stimulating caspase-9/8/3 and inhibiting tumor invasion and metastasis by decreasing the upregulation of matrix metalloproteinase-2/-9 (MMP-2/-9). These molecular pathways of galangin are involved in suppressing different malignancies, such as lung cancer, hepatic cancer, breast cancer, ovarian cancer, gastric cancer, colorectal cancer, retinoblastoma, and osteosarcoma. The present work is emphasized on the anticancer mechanisms of galangin. [Figure not available: see fulltext.]. � 2022, The Author(s) under exclusive licence to Sociedade Brasileira de Farmacognosia.en_US
dc.identifier.doi10.1007/s43450-022-00238-w
dc.identifier.issn1981528X
dc.identifier.urihttp://10.2.3.109/handle/32116/4316
dc.identifier.urlhttps://link.springer.com/10.1007/s43450-022-00238-w
dc.language.isoen_USen_US
dc.publisherSpringer Science and Business Media Deutschland GmbHen_US
dc.subjectAnticanceren_US
dc.subjectApoptosisen_US
dc.subjectFlavonoiden_US
dc.subjectGalanginen_US
dc.subjectPharmacological Activityen_US
dc.titleGalangin, as a Potential Anticancer Agenten_US
dc.title.journalRevista Brasileira de Farmacognosiaen_US
dc.typeReviewen_US
dc.type.accesstypeClosed Accessen_US

Files

Collections

Pharmacology - Research Publications